Business Standard

Cheaper favipiravir brand gets nod, to enter market at Rs 59 a pill

The product comes Pune-based Brinton Pharma; Glenmark's FabiFlu is priced at Rs 73 a tablet

Favipiravir, Umifenovir, atniviral, drugs, pharma, coronavirus, covid-19, sars, cov-2
Premium

Favipiravir was first approved by the regulatory authorities in June under emergency use authorisation to treat Covid-19 patients

Sohini Das Mumbai
After Glenmark's Fabiflu, a second favipiravir (an oral antiviral drug used in Covid-19 treatment)-based formulation got approval from the drug regulator. Pune-based Brinton Pharmaceuticals claimed that it has obtained the nod from the Drug Controller General of India (DCGI) to market its brand Faviton, 

Faviton would be priced at Rs 59 per tablet as against Rs 75 per tablet for FabiFlu. Faviton will be available in a strip of 10 tablets and 50 tablets in a box.

It will be available in 200 mg tablets. Brinton will also be exporting Faviton."Emerging favourable global clinical evidence suggests Favipiravir is an effective treatment option

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in